DEF: Revelation Seeks Shareholder Nod for Warrant Issuance

Revelation Biosciences, Inc. calls a Special Meeting to approve the issuance of common stock exceeding Nasdaq's 20% cap, crucial for funding operations and maintaining listing.

Summary

• Revelation Biosciences, Inc. is holding a Special Meeting of Stockholders on October 15, 2025, at 12:00 p.m. Eastern Time, virtually via Zoom.
• The primary proposal is to approve the reservation and issuance of common stock under Class I Common Stock Warrants, dated September 11, 2025, which may exceed 20% of total outstanding shares, triggering Nasdaq Rule 5635(d) (the Exchange Cap).
• The company entered into warrant inducement letters on September 10, 2025, to induce the exercise of 13,065,000 Class H Warrants, exercisable into 4,355,000 shares at $2.20 per share.
• This transaction generated gross proceeds of approximately $9.6 million.
• The newly issued Class I Warrants are exercisable for five years at $2.20 per share.
• The Record Date for voting is September 11, 2025, with 2,339,306 shares of common stock outstanding.
• Warrant Holders (Sabby Volatility Warrant Master Fund, Ltd., Armistice Capital Master Fund Ltd., and Hudson Bay Master Fund Ltd.) are interested stockholders and will vote their shares proportionally to non-interested stockholders on Proposal 1.
• The Board unanimously recommends voting FOR Proposal 1 and Proposal 2 (adjournment).
• Failure to approve Proposal 1 would require the company to hold stockholder meetings every 60 days and prohibit further stock issuances until approval is obtained.
• The company engaged Advantage Proxy for solicitation, with a fee of $10,000 plus disbursements.

Sentiment

Score: 6

Explanation: While the company successfully raised needed capital and reported positive clinical data, the significant dilution and the necessity of a shareholder vote to exceed Nasdaq's 20% cap indicate a challenging financial position. The financing was critical for continued operations and listing compliance, but at a cost to existing shareholders.

Positives

• Successfully raised approximately $9.6 million in gross proceeds through the warrant inducement.
• Secured financing to advance clinical development programs and maintain operations.
• The warrant inducement offered greater certainty of completion and could be executed quickly compared to other financing alternatives.
• Lower transaction costs were incurred compared to a registered public offering or underwritten financing, maximizing net proceeds.
• Positive topline data from the PRIME Phase 1b clinical study of Gemini-CKD product candidate was released on September 9, 2025.
• The financing helps assure compliance with Nasdaq's minimum $2.5 million stockholders' equity requirement as of September 30, 2025.

Negatives

• The warrant inducement will result in meaningful dilution to existing stockholders.
• The company is required to seek stockholder approval for the issuance of shares exceeding 20% of outstanding shares, indicating a significant capital event relative to its current size.
• Failure to approve Proposal 1 would prohibit the company from issuing further common stock or equivalents and necessitate repeated stockholder meetings every 60 days.

Risks

• Significant dilution to existing stockholders from the warrant inducement.
• Risk of delisting from Nasdaq if the company fails to maintain minimum stockholders' equity or other listing rules.
• Inherent risks faced by biotechnology companies, including the need for continuous financing to fund research, development, and clinical trials.
• Risk of not obtaining stockholder approval for Proposal 1, which would restrict future capital raises and potentially impact Nasdaq listing compliance.

Future Outlook

The company is preparing for FDA meetings regarding the next steps in its clinical program for Gemini-CKD, following positive Phase 1b data. Securing adequate financing is crucial to proceed with these activities and maintain Nasdaq listing compliance.

Management Comments

• "The Board of Directors reviewed a range of financing alternatives, including the issuance of equity, convertible securities, and debt instruments, in determining how best to raise the additional capital required to fund the Company’s operations."
• "After careful consideration, the Board concluded that a warrant inducement transaction was in the best interests of the Company and its stockholders, notwithstanding the significant dilution it will cause."
• "The Board emphasized that the warrant inducement offered greater certainty of completion than other available alternatives, particularly in view of current market conditions and the inherent risks faced by biotechnology companies."
• "The transaction could be executed quickly and reliably, ensuring that the Company would obtain the funding necessary to advance its clinical development programs and maintain its operations."
• "This approach entailed substantially lower transaction costs than a registered public offering, an underwritten financing, or the issuance of new convertible securities."
• "Timing was also a critical factor. The Company’s capital requirements demanded swift action, and a warrant inducement could be completed more rapidly than other financing methods."
• "Although the warrant inducement will result in meaningful dilution to existing stockholders, the Board determined that it represents the most viable and cost-effective method for the Company to obtain the financing it needs under the circumstances."
• "Our Board of Directors believes that the issuance of the Class I Common Stock Warrants is in the best interest of the Company in order to give it the best chance of remaining on Nasdaq."

Industry Context

As a clinical-stage biotechnology company, Revelation Biosciences relies heavily on securing adequate financing to fund its research and development, clinical trials, and regulatory approvals. The warrant inducement reflects a common challenge in the biotech sector to raise capital efficiently, especially given market conditions and inherent risks. The positive Phase 1b data for Gemini-CKD positions the company for further clinical development, but this requires substantial capital.

Corporate Governance

Related Party Transactions

• The warrant inducement involved "certain institutional investors" (the Holders), specifically Sabby Volatility Warrant Master Fund, Ltd., Armistice Capital Master Fund Ltd., and Hudson Bay Master Fund Ltd., who are also significant beneficial owners. Armistice Capital Master Fund Ltd. beneficially owns 9.99% of outstanding shares as of September 11, 2025.

Stakeholder Impact

• Shareholders: Will experience significant dilution from the warrant issuance. Their vote is crucial for the company's ability to maintain Nasdaq listing and continue operations.
• Investors (Warrant Holders): Benefited from the warrant inducement, allowing them to exercise existing warrants and receive new ones, providing capital to the company.
• Employees: Continued operations and advancement of clinical programs secured by the financing will likely maintain job security and strategic direction.
• Customers/Patients (future): Continued development of Gemini-CKD product candidate could eventually lead to new treatments.
• Nasdaq: The company is seeking to comply with Nasdaq listing rules, which is positive for its market presence.

Next Steps

• Hold a Special Meeting of Stockholders on October 15, 2025, to vote on the warrant issuance and potential adjournment.
• Prepare for FDA meetings regarding the next steps in the clinical program for Gemini-CKD.
• File a Current Report on Form 8-K with the SEC within four business days after the Special Meeting to disclose voting results.
• If Proposal 1 is not approved, hold subsequent stockholder meetings every sixty days until approval is obtained.

Key Dates

Recommendation

The company successfully raised critical capital and reported positive clinical data, which are positive developments. However, the significant dilution from the warrant issuance and the ongoing need for shareholder approval to maintain Nasdaq compliance suggest underlying financial challenges. The stock is a "hold" as the positive clinical data and secured financing provide a basis for continued operations, but the dilutive nature of the financing and the inherent risks of a clinical-stage biotech company warrant caution. Investors should monitor the outcome of the shareholder vote and future clinical milestones.

Keywords

Biotechnology, SEC filing, DEF 14A, Revelation Biosciences, Warrants, Stockholder Meeting, Nasdaq, Share Issuance, Dilution, Capital Raise, Clinical Trials, Gemini-CKD, RBIO, Proxy Statement